Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.
Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. However, the company faces a daunting patent cliff.
BMY - Bristol-Myers Squibb Company
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$62.60
DETAILS
HIGH:
$75.00
LOW:
$40.00
MEDIAN:
$60.00
CONSENSUS:
$62.60
UPSIDE:
10.41%
Stock News
Bristol Myers Squibb: Pain First, Payoff Later?
Bristol Myers Squibb remains a Strong Buy, supported by steady performance and undervaluation despite recent underperformance versus the benchmark. BMY boasts a 4.43% forward dividend yield, over 2.7x the sector median, with 36 years of uninterrupted payments and 18 years of consecutive growth. Recent double-beat earnings and consistent estimate beats since 2024 reinforce positive sentiment and justify a premium valuation.
Bristol-Myers Squibb: Cash Flow Machine, Outsized Growth Portfolio, And Inflation Beating Incomes
BMY's growth portfolio now comprises 54.1% of revenues and delivered +9% YoY growth in FQ1'26 against the legacy portfolio's slower erosion, supporting further upside to the currently conservative FY2026 guidance. Strategic partnerships with Jiangsu Hengrui, accretive M&As, and strong uptake of Opdivo Qvantig underpin the company's multi-pronged portfolio renewal efforts, despite the near-term IPRD noise. BMY's intermediate-term top/bottom-line growth prospects are likely to underwhelm due to LOE risks from Eliquis/Opdivo, albeit with secure dividend payouts at 39.2% of free cash flow.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb focuses on specialized medicines in oncology and immunology, and shares sport a low valuation. Johnson & Johnson offers a diversified business model spanning innovative medicines and medical technology.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Merck, AbbVie probed by US lawmakers over China clinical trials: report
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Bristol Myers Squibb (BMY) closed at $58.56, marking a +1.81% move from the previous day.
66 With $1.3 Million. Here Are 3 Hidden Gems to Target
At 66 with $1.3 million, the math is straightforward. A 5% blended yield throws off roughly $65,000 a year before Social Security. The cash flow underneath these three blue chips is what matters most for a retiree. I dug into each dividend to see which ones a 66-year-old can actually rely on. Bristol Myers Squibb:... 66 With $1.3 Million. Here Are 3 Hidden Gems to Target
Here's Why Bristol Myers Squibb (BMY) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb maintains a robust biopharmaceutical portfolio focused on high-stakes oncology and immunology treatments. Johnson & Johnson leverages its massive scale and diversified segments to deliver high net margins and strong cash flow.
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb
Technical indicators show encouraging signs for the three stocks.
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Bristol Myers Squibb (BMY) settling at $55.53, representing a +1.52% change from its previous close.
3 Reasons to Buy Bristol Myers Squibb Stock
Bristol Myers Squibb has a big revenue gap to fill, but it seems up to the challenge. Its robust dividend yield will pay investors handsomely to wait things out.
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is up on Wednesday as the company reported promising clinical observations regarding its ELI-002 7P treatment.
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
3 Stocks to Invest In to Rebalance Your Portfolio
#TheMorningFilter #PortfolioRebalance #StockInvesting These value stocks can balance portfolios heavy in growth stocks—and they're undervalued, too. Watch The Morning Filter: https://www.youtube.com/live/aZZpyIILz3E?si=2QmG7OPY-biqvACZ 00:00:00 Introduction 00:00:32 Bristol-Myers Squibb BMY 00:01:09 Clorox CLX 00:02:50 Lockheed Martin LMT Watch more from Morningstar: 2 Overpriced Stocks to Sell https://youtu.be/2cDEjYfOvKI?si=3eirkC5_eHvZVWzT Ignore the Noise: These 2 Undervalued Stocks Could Be Winners https://www.youtube.com/watch?v=J07j3bAG2_g 3 More Stocks to Buy After Earnings https://www.youtube.com/watch?v=wB9mWstXyuA&t=21s Follow Morningstar on social: Facebook: https://www.facebook.com/MorningstarInc/ X: https://x.com/MorningstarInc Instagram https://www.instagram.com/morningstarinc/?hl=en LinkedIn: https://www.linkedin.com/company/5161/
Price Targets
Bristol Myers price target raised to $54 from $45 at Cantor Fitzgerald
$54.00
(was $59.20)
Cantor Fitzgerald
Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at UBS Ahead of Major Catalyst
$70.00
(was $59.78)
Michael Yee
·
UBS
RBC Capital Starts Bristol-Myers Squibb Co. (BMY) at Sector Perform
$60.00
(was $61.60)
Trung Huynh
·
RBC Capital
Bristol Myers price target raised to $75 from $66 at Piper Sandler
$75.00
(was $60.66)
Piper Sandler
Bristol Myers initiated with an Overweight at Barclays
$75.00
(was $60.30)
Barclays
Bristol Myers price target raised to $40 from $37 at Morgan Stanley
$40.00
(was $61.86)
Terence Flynn
·
Morgan Stanley
Bristol Myers price target raised to $72 from $62 at Guggenheim
$72.00
(was $59.52)
Guggenheim
Bristol Myers price target raised to $60 from $55 at Wells Fargo
$60.00
(was $59.52)
Mohit Bansal
·
Wells Fargo
Bristol Myers price target raised to $66 from $62 at Piper Sandler
$66.00
(was $55.56)
Piper Sandler
Bristol Myers price target raised to $60 from $54 at Leerink
$60.00
(was $56.39)
David Risinger
·
Leerink Partners
Bristol Myers price target raised to $60 from $53 at Scotiabank
$60.00
(was $55.87)
Louise Chen
·
Scotiabank
Bristol Myers upgraded to Buy from Neutral at UBS
$65.00
(was $56.41)
UBS
Bristol Myers price target raised to $37 from $36 at Morgan Stanley
$37.00
(was $52.63)
Morgan Stanley
Bristol Myers upgraded to Buy from Neutral at Guggenheim
$62.00
(was $51.20)
Guggenheim
Bristol Myers price target raised to $53 from $50 at HSBC
$53.00
(was $50.68)
HSBC
Bristol-Myers Squibb Co. (BMY) PT Raised to $53 at Scotiabank
$53.00
(was $50.96)
Louis Chen
·
Scotiabank
Truist Securities on Bristol-Myers Squibb Co. (BMY): 'overall positive'
$65.00
(was $50.98)
Srikripa Devarakonda
·
Truist Financial
Bristol Myers downgraded to Neutral from Outperform at Daiwa
$42.00
(was $45.85)
Narumi Nakagiri
·
Daiwa
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
$84.00
(was $47.12)
David Macdonald
·
Truist Financial
Bristol Myers price target lowered to $68 from $70 at Jefferies
$68.00
(was $48.52)
Akash Tewari
·
Jefferies